Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01394627 · ClinicalTrials.gov registry record · NA
Hypoglycemia and the Mineralocorticoid Receptor
A NA study of Hypoglycemia, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01394627: Completed NA study of Hypoglycemia, sponsored by Brigham and Women's Hospital.
NCT01394627 is a NA study of Hypoglycemia that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 21 participants, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01394627, a NA study of Hypoglycemia, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to look at whether blockade of the mineralocorticoid receptor will result in changes in the cardiovascular and inflammatory response to hypoglycemia.
Primary Outcome
Modified oxford procedures was performed in duplicate immediately prior to start of the hypoglycemic clamp and during the last 30 min of the clamp (i.e. during the last 30 min of exposure to 2 hours of hypoglycemia).. We calculated the baroreflex sensitivity (the relationship between RR interval and change in systolic blood pressure defined as the change in the inter-beat cardiac interval in milliseconds per unit change in blood pressure in mmHg) at each time point and then the change in baroref
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eplerenone
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-01 |
| Est. Completion | 2016-08 |
| Phase | NA |
What the finished NCT01394627 record still lists
NCT01394627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Hypoglycemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01394627 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01394627 about?
NCT01394627 is a clinical study titled "Hypoglycemia and the Mineralocorticoid Receptor". The purpose of this study is to look at whether blockade of the mineralocorticoid receptor will result in changes in the cardiovascular and inflammatory response to hypoglycemia.
What is the current status of trial NCT01394627?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2011-01. Estimated completion is 2016-08.
What conditions does trial NCT01394627 study?
This clinical trial studies the following conditions: Hypoglycemia.
What interventions are being tested in trial NCT01394627?
The interventions under investigation include: Placebo (DRUG), Eplerenone (DRUG).
Who is sponsoring clinical trial NCT01394627?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01394627 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoglycemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01394627's enrollment target sits among peer trials
21 28th of 40 higher than 13 of 40 other Hypoglycemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoglycemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
RECRUITING · NA
-
Enhancing Shared Decision-making to Guide Care for People With Dementia and Diabetes
RECRUITING · NA
-
Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation
RECRUITING · NA
-
Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes
RECRUITING · NA
-
Monitoring Exhaled Breath to Noninvasively Detect Glycemic Events
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia